Infinity Pharmaceuticals | INFI - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Cipla INR 7.96B 39.9M 2025-09
Clal Biotechnology ILS 5.73M 1.71M 2023-12
Compugen USD 90.6M 83.14M 2025-12
CSL USD 2.16B 633M 2025-06
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 7.27B 2.52B 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Grifols EUR 979.78M 334.84M 2024-12
Incyte USD 3.58B 650.78M 2025-12
Infinity Pharmaceuticals USD 17.75M 7.99M 2023-06
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
J&J USD 19.71B 1.48B 2025-12
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
Plus Therapeutics USD 4.26M 9.03M 2025-12
Roche Holding CHF 7.55B 579M 2025-06
TG Therapeutics USD 199.51M 21.2M 2025-12